Mark Biagi

857 total citations
30 papers, 543 citations indexed

About

Mark Biagi is a scholar working on Molecular Medicine, Pharmacology and Infectious Diseases. According to data from OpenAlex, Mark Biagi has authored 30 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Medicine, 11 papers in Pharmacology and 10 papers in Infectious Diseases. Recurrent topics in Mark Biagi's work include Antibiotic Resistance in Bacteria (14 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Antibiotic Use and Resistance (5 papers). Mark Biagi is often cited by papers focused on Antibiotic Resistance in Bacteria (14 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Antibiotic Use and Resistance (5 papers). Mark Biagi collaborates with scholars based in United States and Japan. Mark Biagi's co-authors include Eric Wenzler, David A. Butler, Shitalben Patel, Migyung Lee, Larry H. Danziger, Rodrigo E. Mendes, Zackery P. Bulman, Nathan P. Wiederhold, Susan C Bleasdale and Xing Tan and has published in prestigious journals such as Journal of Clinical Microbiology, Antimicrobial Agents and Chemotherapy and Atherosclerosis.

In The Last Decade

Mark Biagi

26 papers receiving 529 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Biagi United States 13 311 196 162 155 129 30 543
Lauro Vieira Perdigão Neto Brazil 15 396 1.3× 228 1.2× 214 1.3× 97 0.6× 123 1.0× 56 610
Kwok-Woon Yu Taiwan 13 272 0.9× 103 0.5× 240 1.5× 196 1.3× 158 1.2× 17 638
F. Rossi Brazil 11 370 1.2× 111 0.6× 134 0.8× 149 1.0× 98 0.8× 21 596
Thomas H. McConville United States 10 443 1.4× 199 1.0× 178 1.1× 115 0.7× 147 1.1× 14 656
Andrew Henderson Australia 14 235 0.8× 129 0.7× 209 1.3× 94 0.6× 117 0.9× 42 529
Donatella Lombardo Italy 11 289 0.9× 163 0.8× 168 1.0× 64 0.4× 125 1.0× 19 551
Gladys Villas Boas do Prado Brazil 11 304 1.0× 204 1.0× 160 1.0× 54 0.3× 125 1.0× 16 550
Marcello Meledandri Italy 11 314 1.0× 158 0.8× 178 1.1× 67 0.4× 98 0.8× 14 502
Liangfei Xu China 2 394 1.3× 150 0.8× 120 0.7× 94 0.6× 54 0.4× 4 484
Suchitha Bheemreddy United States 12 318 1.0× 164 0.8× 261 1.6× 66 0.4× 197 1.5× 13 642

Countries citing papers authored by Mark Biagi

Since Specialization
Citations

This map shows the geographic impact of Mark Biagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Biagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Biagi more than expected).

Fields of papers citing papers by Mark Biagi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Biagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Biagi. The network helps show where Mark Biagi may publish in the future.

Co-authorship network of co-authors of Mark Biagi

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Biagi. A scholar is included among the top collaborators of Mark Biagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Biagi. Mark Biagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Biagi, Mark, et al.. (2025). Graded isavuconazonium sulfate challenge in a patient with hypersensitivity to fluconazole. IDCases. 42. e02355–e02355.
2.
Bulman, Zackery P., et al.. (2024). Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: A retrospective cohort study. International Journal of Antimicrobial Agents. 64(5). 107321–107321. 2 indexed citations
3.
Biagi, Mark, et al.. (2024). Association of Race or Ethnicity With Extended-Spectrum Beta-Lactamase Production in Escherichia Coli: A Case Control Study. Open Forum Infectious Diseases. 11(10). ofae516–ofae516.
4.
Biagi, Mark, et al.. (2022). Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales. Diagnostic Microbiology and Infectious Disease. 103(2). 115674–115674. 12 indexed citations
5.
Biagi, Mark, et al.. (2022). Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility. Microbiology Spectrum. 10(3). e0054222–e0054222. 10 indexed citations
6.
Rebold, Nicholas, Taylor Morrisette, Abdalhamid M Lagnf, et al.. (2021). Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Open Forum Infectious Diseases. 8(12). ofab554–ofab554. 24 indexed citations
7.
8.
Lee, Michelle, et al.. (2020). Activity of aztreonam in combination with ceftazidime–avibactam against serine- and metallo-β-lactamase–producing Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease. 99(1). 115227–115227. 37 indexed citations
9.
Butler, David A., Mark Biagi, Vikas Gupta, et al.. (2020). Development of a 51-hospital Chicagoland regional antibiogram and comparison to local hospital and national surveillance data. Infection Control and Hospital Epidemiology. 41(12). 1409–1418. 5 indexed citations
10.
Biagi, Mark, et al.. (2020). Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens. Antimicrobial Agents and Chemotherapy. 64(4). 13 indexed citations
11.
Biagi, Mark, et al.. (2020). Successful treatment of trichomoniasis with tinidazole following desensitization in a patient allergic to metronidazole. International Journal of STD & AIDS. 32(1). 89–91. 3 indexed citations
12.
Butler, David A., et al.. (2019). Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat. Current Infectious Disease Reports. 21(12). 46–46. 52 indexed citations
13.
14.
Biagi, Mark, Nathan P. Wiederhold, Connie Fe C. Gibas, et al.. (2019). Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria. Open Forum Infectious Diseases. 6(7). ofz262–ofz262. 85 indexed citations
15.
16.
Badowski, Melissa E., et al.. (2016). New Antiretroviral Treatment for HIV. Infectious Diseases and Therapy. 5(3). 329–352. 12 indexed citations
17.
18.
19.
Subissi, Alessandro, Marco Criscuoli, Mark Biagi, & W Murmann. (1983). Acute effects on plasma lipids in the rat of a new long-acting nicotinic acid derivative: LG 13979. Journal of Pharmacy and Pharmacology. 35(9). 571–575. 2 indexed citations
20.
Subissi, Alessandro, Mark Biagi, & W Murmann. (1980). Some aspects of sorbinicate pharmacokinetics.. PubMed. 30(8). 1278–84. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lauro Vieira Perdigão Neto Breakdown of academic impact, for papers by Kwok-Woon Yu Breakdown of academic impact, for papers by F. Rossi Breakdown of academic impact, for papers by Thomas H. McConville Breakdown of academic impact, for papers by Andrew Henderson Breakdown of academic impact, for papers by Donatella Lombardo Breakdown of academic impact, for papers by Gladys Villas Boas do Prado Breakdown of academic impact, for papers by Marcello Meledandri Breakdown of academic impact, for papers by Liangfei Xu Breakdown of academic impact, for papers by Suchitha Bheemreddy
Rankless by CCL
2026